PMID- 37510177
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230731
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 13
IP  - 14
DP  - 2023 Jul 21
TI  - Clinical Impact of the BIOFIRE Blood Culture Identification 2 Panel in Adult 
      Patients with Bloodstream Infection: A Multicentre Observational Study in the 
      United Arab Emirates.
LID - 10.3390/diagnostics13142433 [doi]
LID - 2433
AB  - Rapid pathogen identification is key to the proper management of patients with 
      bloodstream infections (BSIs), especially in the intensive care setting. This 
      multicentre study compared the time to pathogen identification results in 185 
      patients admitted to intensive care with a confirmed BSI, using conventional 
      methods (n = 99 patients) and upon implementation of the BIOFIRE((R)) Blood Culture 
      Identification 2 (BCID2) Panel, a rapid molecular test allowing for the 
      simultaneous identification of 43 BSI-related nucleic acids targets (n = 86 
      patients). The median time to result informing optimal antibiotic therapy was 
      significantly shorter following the implementation of the BCID2 Panel (92 vs. 28 
      h pre vs. post BCID2 implementation; p < 0.0001). BCID2 usage in addition to 
      conventional methods led to the identification of at least one pathogen in 98.8% 
      patients vs. 87.9% using conventional methods alone (p = 0.003) and was 
      associated with a lower 30-day mortality (17.3% vs. 31.6%, respectively; p = 
      0.019). This study at three intensive care units in the United Arab Emirates 
      therefore demonstrates that, in addition to conventional microbiological methods 
      and an effective antimicrobial stewardship program, the BCID2 Panel could improve 
      the clinical outcome of patients admitted to the intensive care unit with a 
      confirmed BSI.
FAU - Senok, Abiola
AU  - Senok A
AUID- ORCID: 0000-0001-6382-198X
AD  - College of Medicine, Mohammed Bin Rashid University of Medicine and Health 
      Sciences, Dubai P.O. Box 505055, United Arab Emirates.
FAU - Dabal, Laila Al
AU  - Dabal LA
AD  - Infectious Diseases Unit, Rashid Hospital, Dubai P.O. Box 4545, United Arab 
      Emirates.
FAU - Alfaresi, Mubarak
AU  - Alfaresi M
AD  - Pathology and Laboratory Medicine, Zayed Military Hospital, Abu Dhabi P.O. Box 
      72763, United Arab Emirates.
FAU - Habous, Maya
AU  - Habous M
AD  - Microbiology and Infection Control Unit, Pathology Department, Rashid Hospital, 
      Dubai P.O. Box 4545, United Arab Emirates.
FAU - Celiloglu, Handan
AU  - Celiloglu H
AD  - Microbiology Department, Mediclinic City Hospital, Dubai Healthcare City, Dubai 
      P.O. Box 505004, United Arab Emirates.
FAU - Bashiri, Safia
AU  - Bashiri S
AD  - Infectious Diseases Unit, Rashid Hospital, Dubai P.O. Box 4545, United Arab 
      Emirates.
FAU - Almaazmi, Naama
AU  - Almaazmi N
AD  - Infectious Diseases Unit, Rashid Hospital, Dubai P.O. Box 4545, United Arab 
      Emirates.
FAU - Ahmed, Hassan
AU  - Ahmed H
AD  - Infectious Diseases Unit, Rashid Hospital, Dubai P.O. Box 4545, United Arab 
      Emirates.
FAU - Mohmed, Ayman A
AU  - Mohmed AA
AD  - Intensive Care Unit, Sheikh Khalifa General Hospital, Umm Al Quwain P.O. Box 499, 
      United Arab Emirates.
FAU - Bahaaldin, Omar
AU  - Bahaaldin O
AD  - Microbiology and Infection Control Unit, Pathology Department, Rashid Hospital, 
      Dubai P.O. Box 4545, United Arab Emirates.
FAU - Elimam, Maimona Ahmed Elsiddig
AU  - Elimam MAE
AD  - Microbiology and Infection Control Unit, Pathology Department, Rashid Hospital, 
      Dubai P.O. Box 4545, United Arab Emirates.
FAU - Rizvi, Irfan Hussain
AU  - Rizvi IH
AD  - Microbiology Department, Mediclinic City Hospital, Dubai Healthcare City, Dubai 
      P.O. Box 505004, United Arab Emirates.
FAU - Olowoyeye, Victory
AU  - Olowoyeye V
AD  - College of Medicine, Mohammed Bin Rashid University of Medicine and Health 
      Sciences, Dubai P.O. Box 505055, United Arab Emirates.
FAU - Powell, Michaela
AU  - Powell M
AD  - Data Science Department, bioMerieux Inc., Salt Lake City, UT 84108, USA.
FAU - Salama, Basel
AU  - Salama B
AD  - Medical Affairs, bioMerieux, Dubai P.O. Box 505201, United Arab Emirates.
LA  - eng
PT  - Journal Article
DEP - 20230721
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC10378530
OTO - NOTNLM
OT  - BCID
OT  - BCID2
OT  - BIOFIRE Blood Culture Identification Panel
OT  - automated multiplex PCR
OT  - blood culture
OT  - bloodstream infection
OT  - optimal antimicrobial therapy
OT  - rapid molecular diagnostics
OT  - sepsis
OT  - targeted antimicrobial therapy
COIS- M.P. and B.S. are employees of bioMerieux. All other authors declare no conflict 
      of interest. bioMerieux supported this study in the form of technical assistance 
      funding and provision of reagents. The funder had a role in the statistical 
      analysis of the data and in the writing of the manuscript.
EDAT- 2023/07/29 11:46
MHDA- 2023/07/29 11:47
PMCR- 2023/07/21
CRDT- 2023/07/29 01:16
PHST- 2023/05/30 00:00 [received]
PHST- 2023/07/10 00:00 [revised]
PHST- 2023/07/18 00:00 [accepted]
PHST- 2023/07/29 11:47 [medline]
PHST- 2023/07/29 11:46 [pubmed]
PHST- 2023/07/29 01:16 [entrez]
PHST- 2023/07/21 00:00 [pmc-release]
AID - diagnostics13142433 [pii]
AID - diagnostics-13-02433 [pii]
AID - 10.3390/diagnostics13142433 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2023 Jul 21;13(14):2433. doi: 10.3390/diagnostics13142433.